md	1:0,0,0,0
rem	1:0,0,0,0
em	1:0,0,0,0
bers:	1:0,0,0,0
t	1:0,0,0,0
h	1:0,0,0,0;1:0,0,0,0
e	1:0,0,0,0;1:0,0,0,0
d	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
isco	1:0,0,0,0
v	1:0,0,0,0
ery	1:0,0,0,0
of	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
a	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
n	1:0,0,0,0;1:0,0,0,0
s	1:0,0,0,0;1:0,0,0,0
’s	1:0,0,0,0
b	1:0,0,0,0
c	1:0,0,0,0
illu	1:0,0,0,0
he	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
xvas	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
alloxved	1:0,0,0,0
to	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
keep	1:0,0,0,0
his	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
posi	1:0,0,0,0
antigen	1:0,0,0,0
and	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
carry	1:0,0,0,0
huge	1:0,0,0,0
numbers	1:0,0,0,0
■	1:0,0,0,0
centiirv	1:0,0,0,0
ago	1:0,0,0,0
norwegian	1:0,0,0,0
physi	1:0,0,0,0
tion	1:0,0,0,0
as	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
leprosy	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
medical	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
officer	1:0,0,0,0
for	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
macrophages	1:0,0,0,0
loaded	1:0,0,0,0
xvith	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
bacilli	1:0,0,0,0
cian	1:0,0,0,0
dr.	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
c'.erhard	1:0,0,0,0
arinaner	1:0,0,0,0
hansen	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
that	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
the	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
phagocytes	1:0,0,0,0
are	1:0,0,0,0
unable	1:0,0,0,0
all	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
ol	1:0,0,0,0;1:0,0,0,0
norxvav,	1:0,0,0,0
helped	1:0,0,0,0;1:0,0,0,0
bring	1:0,0,0,0
reported	1:0,0,0,0;1:0,0,0,0
tlic	1:0,0,0,0
society	1:0,0,0,0
destroy.	1:0,0,0,0
about	1:0,0,0,0;1:0,0,0,0
laxv	1:0,0,0,0
required	1:0,0,0,0
pre	1:0,0,0,0
christiania	1:0,0,0,0;1:0,0,0,0
(oslo)	1:0,0,0,0
diseo\erv	1:0,0,0,0
in	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
an	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
immunotherapy	1:0,0,0,0
trial	1:0,0,0,0
cautionary	1:0,0,0,0
isolation	1:0,0,0,0
pa	1:0,0,0,0
every	1:0,0,0,0
leprous	1:0,0,0,0
tid)erele	1:0,0,0,0
“small	1:0,0,0,0
ward	1:0,0,0,0
f.	1:0,0,0,0
bullock	1:0,0,0,0
university	1:0,0,0,0;1:0,0,0,0
tients	1:0,0,0,0
from	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
their	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
families.	1:0,0,0,0
stall-like	1:0,0,0,0
bodies,	1:0,0,0,0
much	1:0,0,0,0
resembling	1:0,0,0,0
kentucky	1:0,0,0,0
associates	1:0,0,0,0
induced	1:0,0,0,0
student	1:0,0,0,0
marine	1:0,0,0,0
fauna,	1:0,0,0,0
han	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
l)aeteria.”	1:0,0,0,0
although	1:0,0,0,0
was	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
imsue-	1:0,0,0,0
xveak	1:0,0,0,0
.systemic	1:0,0,0,0
hypersensitivity	1:0,0,0,0;1:0,0,0,0
sen	1:0,0,0,0;1:0,0,0,0
xvrote	1:0,0,0,0
book	1:0,0,0,0
on	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
darxx'inisin	1:0,0,0,0
eessful	1:0,0,0,0
infecting	1:0,0,0,0
eats	1:0,0,0,0
rabbits	1:0,0,0,0
six	1:0,0,0,0
nine	1:0,0,0,0
lepromatous	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
patients	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
by	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
with	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
these	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
bodies	1:0,0,0,0
thought	1:0,0,0,0
they	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
administering	1:0,0,0,0
sensitized	1:0,0,0,0
lympbo-	1:0,0,0,0
were	1:0,0,0,0
etiologie	1:0,0,0,0
agents	1:0,0,0,0;1:0,0,0,0
cytes	1:0,0,0,0
or	1:0,0,0,0
transfer	1:0,0,0,0
factor	1:0,0,0,0
sub	1:0,0,0,0
hence	1:0,0,0,0
suggested	1:0,0,0,0
ehronie	1:0,0,0,0
jects	1:0,0,0,0
high	1:0,0,0,0;1:0,0,0,0
degree	1:0,0,0,0;1:0,0,0,0
delayed	1:0,0,0,0
disease	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
might	1:0,0,0,0
caused	1:0,0,0,0;1:0,0,0,0
hv	1:0,0,0,0
miero-	1:0,0,0,0
lepromin.	1:0,0,0,0
organisin	1:0,0,0,0
eight	1:0,0,0,0
years	1:0,0,0,0;1:0,0,0,0
belore	1:0,0,0,0
robert	1:0,0,0,0;1:0,0,0,0
more	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
successfid	1:0,0,0,0
approach	1:0,0,0,0
made	1:0,0,0,0
koch	1:0,0,0,0
discox	1:0,0,0,0
ered	1:0,0,0,0
tubercle	1:0,0,0,0
bacil	1:0,0,0,0
soo	1:0,0,0,0
duk	1:0,0,0,0
lim	1:0,0,0,0
unix'ersity	1:0,0,0,0
lus	1:0,0,0,0
1ss2.	1:0,0,0,0
korea	1:0,0,0,0
a.	1:0,0,0,0
good	1:0,0,0,0
hansen,	1:0,0,0,0
born	1:0,0,0,0
bergen	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
ls41,	1:0,0,0,0
infusion	1:0,0,0,0
massive	1:0,0,0,0
doses	1:0,0,0,0
worked	1:0,0,0,0
way	1:0,0,0,0
through	1:0,0,0,0
lymphocytes	1:0,0,0,0
unmatched	1:0,0,0,0
school	1:0,0,0,0;1:0,0,0,0
teaching	1:0,0,0,0
at	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
girl’s	1:0,0,0,0
donors	1:0,0,0,0
effort	1:0,0,0,0
induce	1:0,0,0,0
substituting	1:0,0,0,0
anatomy	1:0,0,0,0
dem	1:0,0,0,0
limited	1:0,0,0,0
graft	1:0,0,0,0
x'ersus	1:0,0,0,0
host	1:0,0,0,0
reaction	1:0,0,0,0;1:0,0,0,0
onstrator.	1:0,0,0,0
received	1:0,0,0,0
14	1:0,0,0,0
patients.	1:0,0,0,0
xveek-	1:0,0,0,0
honors	1:0,0,0,0
ly	1:0,0,0,0
infusions,	1:0,0,0,0
periods	1:0,0,0,0
up	1:0,0,0,0
16	1:0,0,0,0
1866	1:0,0,0,0
followins;	1:0,0,0,0
xveeks,	1:0,0,0,0
internship	1:0,0,0,0
national	1:0,0,0,0
hospi	1:0,0,0,0
xvho	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
had	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
failed	1:0,0,0,0
respond	1:0,0,0,0
other	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
tal	1:0,0,0,0
served	1:0,0,0,0
physician	1:0,0,0,0
fishing	1:0,0,0,0;1:0,0,0,0
forms	1:0,0,0,0
treatment.	1:0,0,0,0
following	1:0,0,0,0
im	1:0,0,0,0;1:0,0,0,0
community	1:0,0,0,0
lofoten	1:0,0,0,0
islands.	1:0,0,0,0
munotherapy	1:0,0,0,0
shoxved	1:0,0,0,0
softer,	1:0,0,0,0
1868,	1:0,0,0,0
when	1:0,0,0,0;1:0,0,0,0
became	1:0,0,0,0;1:0,0,0,0
smaller	1:0,0,0,0
external	1:0,0,0,0
lesions	1:0,0,0,0
fewer	1:0,0,0,0
sistant	1:0,0,0,0
st.	1:0,0,0,0
jorgan	1:0,0,0,0
hospital	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
baccilli	1:0,0,0,0
tissues.	1:0,0,0,0
bergen,	1:0,0,0,0
than	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
one	1:0,0,0,0;1:0,0,0,0
percent	1:0,0,0,0
meeting	1:0,0,0,0;1:0,0,0,0
clinicians	1:0,0,0,0
population	1:0,0,0,0
city	1:0,0,0,0
its	1:0,0,0,0;1:0,0,0,0
expressed	1:0,0,0,0
cautious	1:0,0,0,0
optimism	1:0,0,0,0
enx’irons	1:0,0,0,0
suffered	1:0,0,0,0;1:0,0,0,0
leprosy.	1:0,0,0,0
txvo	1:0,0,0,0
drugs	1:0,0,0,0
have	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
been	1:0,0,0,0
recently	1:0,0,0,0
time	1:0,0,0,0
many	1:0,0,0,0;1:0,0,0,0
introduced	1:0,0,0,0
therapy.	1:0,0,0,0
clo-	1:0,0,0,0
physicians	1:0,0,0,0
who	1:0,0,0,0
believed	1:0,0,0,0
fazamine	1:0,0,0,0
found	1:0,0,0,0;1:0,0,0,0
effective	1:0,0,0,0
wars	1:0,0,0,0
hereditary	1:0,0,0,0
sulfone-resistant	1:0,0,0,0
cases	1:0,0,0,0
sex’ere	1:0,0,0,0
sen’s	1:0,0,0,0
chief	1:0,0,0,0;1:0,0,0,0
father-in-law.	1:0,0,0,0
gerhard	1:0,0,0,0
armauer	1:0,0,0,0
lepra	1:0,0,0,0
reactions,	1:0,0,0,0
antibiotic	1:0,0,0,0
daniel	1:0,0,0,0
cornelius	1:0,0,0,0
danielssen.	1:0,0,0,0
rifampicin	1:0,0,0,0
destroy	1:0,0,0,0
two	1:0,0,0,0
scientists	1:0,0,0,0
heated	1:0,0,0,0
disagree-	1:0,0,0,0
delixered	1:0,0,0,0
lectures	1:0,0,0,0
m.	1:0,0,0,0
leprae	1:0,0,0,0
rapidly	1:0,0,0,0
any	1:0,0,0,0
ments	1:0,0,0,0
this	1:0,0,0,0;1:0,0,0,0
subject,	1:0,0,0,0
theory	1:0,0,0,0
evolution.	1:0,0,0,0
later	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
drug.	1:0,0,0,0
studies	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
k.	1:0,0,0,0
prab-	1:0,0,0,0
concluded	1:0,0,0,0
epidemiologic	1:0,0,0,0
jvears	1:0,0,0,0
heart	1:0,0,0,0
dis	1:0,0,0,0
hakaran’s	1:0,0,0,0
group	1:0,0,0,0
garville	1:0,0,0,0
lep	1:0,0,0,0
ease	1:0,0,0,0
february,	1:0,0,0,0
1912	1:0,0,0,0
xx'hile	1:0,0,0,0
must	1:0,0,0,0
be	1:0,0,0,0;1:0,0,0,0
rosy	1:0,0,0,0
center,	1:0,0,0,0
indicating	1:0,0,0,0
is	1:0,0,0,0;1:0,0,0,0
visiting	1:0,0,0,0
toxvn	1:0,0,0,0
floro	1:0,0,0,0
specific	1:0,0,0,0
agent.	1:0,0,0,0
1870	1:0,0,0,0
.	1:0,0,0,0
o	1:0,0,0,0;1:0,0,0,0
p	1:0,0,0,0;1:0,0,0,0
x	1:0,0,0,0
essential	1:0,0,0,0
organisms,	1:0,0,0,0
may	1:0,0,0,0;1:0,0,0,0
ex	1:0,0,0,0
traxel	1:0,0,0,0
grant	1:0,0,0,0
uni-	1:0,0,0,0
norxvay’s	1:0,0,0,0
xvestern	1:0,0,0,0
coast	1:0,0,0,0
died	1:0,0,0,0
plain	1:0,0,0,0
predilection	1:0,0,0,0
nerxes,	1:0,0,0,0
\ersity	1:0,0,0,0
went	1:0,0,0,0
abroad	1:0,0,0,0
home	1:0,0,0,0
friend.	1:0,0,0,0
only	1:0,0,0,0
skin	1:0,0,0,0;1:0,0,0,0
sites	1:0,0,0,0
free	1:0,0,0,0
study	1:0,0,0,0
bistopathologic	1:0,0,0,0
methods	1:0,0,0,0
child,	1:0,0,0,0
son	1:0,0,0,0
studied	1:0,0,0,0
medicine,	1:0,0,0,0
,	1:0,0,0,0
also	1:0,0,0,0
lead	1:0,0,0,0
de	1:0,0,0,0
bonn	1:0,0,0,0
vienna	1:0,0,0,0
obserx	1:0,0,0,0
ed	1:0,0,0,0
bergen’s	1:0,0,0,0
tubercu	1:0,0,0,0
velopment	1:0,0,0,0
chemotherapeutic	1:0,0,0,0
losis	1:0,0,0,0
1929.	1:0,0,0,0
rod-shaped	1:0,0,0,0
acid-fast	1:0,0,0,0
organisms	1:0,0,0,0
inhibit	1:0,0,0,0
utilization	1:0,0,0,0
recent	1:0,0,0,0;1:0,0,0,0
research	1:0,0,0,0;1:0,0,0,0
albert	1:0,0,0,0
ludxvig	1:0,0,0,0
neisser	1:0,0,0,0
first	1:0,0,0,0
modern	1:0,0,0,0
studies.	1:0,0,0,0
compound.	1:0,0,0,0
stained	1:0,0,0,0
.successfully	1:0,0,0,0
1879.	1:0,0,0,0
hansen’s	1:0,0,0,0;1:0,0,0,0
revdexved	1:0,0,0,0
folloxving	1:0,0,0,0
year	1:0,0,0,0
named	1:0,0,0,0
tore	1:0,0,0,0
go-	1:0,0,0,0
10th	1:0,0,0,0
international	1:0,0,0,0
organism,	1:0,0,0,0
noxv	1:0,0,0,0
classified	1:0,0,0,0
myco	1:0,0,0,0
dal	1:0,0,0,0
associate	1:0,0,0,0
addis	1:0,0,0,0
congress	1:0,0,0,0
last	1:0,0,0,0
summer	1:0,0,0,0
bv	1:0,0,0,0
ababa	1:0,0,0,0
institute	1:0,0,0,0
indicates	1:0,0,0,0
bacterium	1:0,0,0,0
baccilus	1:0,0,0,0
leprae,	1:0,0,0,0
but	1:0,0,0,0;1:0,0,0,0
1000	1:0,0,0,0
participants	1:0,0,0,0
pathogen	1:0,0,0,0
bore	1:0,0,0,0
75	1:0,0,0,0
countries.	1:0,0,0,0
65	1:0,0,0,0
papers	1:0,0,0,0
seems	1:0,0,0,0
eponym.	1:0,0,0,0
fectious	1:0,0,0,0
prevalence	1:0,0,0,0
indi	1:0,0,0,0
presented	1:0,0,0,0
dealt	1:0,0,0,0
cates,	1:0,0,0,0
subclinical	1:0,0,0,0
infections	1:0,0,0,0
immunologic	1:0,0,0,0
lepro	1:0,0,0,0
efforts	1:0,0,0,0
culture	1:0,0,0,0
commonly	1:0,0,0,0
folloxv	1:0,0,0,0
exposure	1:0,0,0,0
sy	1:0,0,0,0
xx’hich	1:0,0,0,0
recognized	1:0,0,0,0
bacillus	1:0,0,0,0
transmit	1:0,0,0,0
organisms.	1:0,0,0,0
using	1:0,0,0,0
lymphocyte	1:0,0,0,0
trans	1:0,0,0,0
mune	1:0,0,0,0
deficiency	1:0,0,0,0
disorder	1:0,0,0,0
xvell	1:0,0,0,0
animals	1:0,0,0,0
failed,	1:0,0,0,0
xvhen	1:0,0,0,0
inoc	1:0,0,0,0
formations	1:0,0,0,0
determine	1:0,0,0,0
immune	1:0,0,0,0
ulated	1:0,0,0,0
eve	1:0,0,0,0
xvoman	1:0,0,0,0
infectious	1:0,0,0,0
disease.	1:0,0,0,0
neural	1:0,0,0,0
material	1:0,0,0,0
responses,	1:0,0,0,0
investigators	1:0,0,0,0
often	1:0,0,0,0
lack	1:0,0,0,0
positive	1:0,0,0,0
response	1:0,0,0,0
fourth	1:0,0,0,0
patient’s	1:0,0,0,0
cutaneous	1:0,0,0,0
nodule	1:0,0,0,0
xvith-	1:0,0,0,0
cellular	1:0,0,0,0
immunity,	1:0,0,0,0
no	1:0,0,0,0
subjects	1:0,0,0,0
lived	1:0,0,0,0
lepromin	1:0,0,0,0
out	1:0,0,0,0
experimental	1:0,0,0,0
subject’s	1:0,0,0,0
con	1:0,0,0,0
endemic	1:0,0,0,0
area	1:0,0,0,0
over	1:0,0,0,0
year.	1:0,0,0,0
lex	1:0,0,0,0
els	1:0,0,0,0
circulating	1:0,0,0,0
antibody	1:0,0,0,0
sent,	1:0,0,0,0
lost	1:0,0,0,0
post.	1:0,0,0,0
since	1:0,0,0,0
79	1:0,0,0,0
md.	1:0,0,0,0
march.	1:0,0,0,0
1974	1:0,0,0,0